NCT03428347View on ClinicalTrials.gov

An Open Study of the Safety and Pharmacokinetics of a Medicinal Product for Emergency Prevention of Ebola

PHASE1CompletedINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

March 12, 2018

Primary Completion Date

December 29, 2018

Study Completion Date

December 29, 2018

Conditions
Healthy
Interventions
BIOLOGICAL

GamEMab

drug for emergency prevention of Ebola based on recombinant monoclonal antibodies

Trial Locations (1)

Unknown

Research Institute of Influenza, Saint Petersburg

All Listed Sponsors
collaborator

Research Institute of Influenza, Sankt-Peterburg, Russian Federation

UNKNOWN

lead

Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation

OTHER

NCT03428347 - An Open Study of the Safety and Pharmacokinetics of a Medicinal Product for Emergency Prevention of Ebola | Biotech Hunter | Biotech Hunter